1
|
Grellier N, Sokol H, Seksik P. Gut dysbiosis in Crohn's disease: Never so close to solving the chicken-and-egg enigma: Commentary to "Gut microbiome composition is associated with future onset of Crohn's disease in healthy first-degree relatives, by Raygoza Garay JA et al., Gastroenterology 2023". Clin Res Hepatol Gastroenterol 2024; 48:102272. [PMID: 38145785 DOI: 10.1016/j.clinre.2023.102272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Accepted: 12/20/2023] [Indexed: 12/27/2023]
Abstract
Crohn's disease (CD) is a chronic disease of the digestive tract whose pathogenesis remains not fully understood. Several studies have implicated the gut microbiota as a key player in the onset of gut inflammation. However, most of the data is based on case-control studies comparing patients with established disease with controls, usually healthy individuals. The study by Raygoza Garay and colleagues shows for the first time that changes in the composition of the gut microbiota precede CD onset by up to five years. The authors developed a microbiome risk score using a machine-learning model that included bacterial composition and clinical variables from a large cohort of healthy first-degree relatives of patients with CD. This study provides strong evidence that the alterations of the gut microbiota is causal in CD pathogenesis and suggest that early intervention targeting it may be an appropriate preventive strategy.
Collapse
Affiliation(s)
- Nathan Grellier
- Poitiers University Hospital, Department of Hepato-Gastroenterology, Poitiers, France.
| | - Harry Sokol
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Paris, France; Gastroenterology department, Saint Antoine Hospital, APHP, Paris, France
| | - Philippe Seksik
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Paris, France; Gastroenterology department, Saint Antoine Hospital, APHP, Paris, France
| |
Collapse
|
2
|
Raygoza Garay JA, Turpin W, Lee SH, Smith MI, Goethel A, Griffiths AM, Moayyedi P, Espin-Garcia O, Abreu M, Aumais GL, Bernstein CN, Biron IA, Cino M, Deslandres C, Dotan I, El-Matary W, Feagan B, Guttman DS, Huynh H, Dieleman LA, Hyams JS, Jacobson K, Mack D, Marshall JK, Otley A, Panaccione R, Ropeleski M, Silverberg MS, Steinhart AH, Turner D, Yerushalmi B, Paterson AD, Xu W, Croitoru K. Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives. Gastroenterology 2023; 165:670-681. [PMID: 37263307 DOI: 10.1053/j.gastro.2023.05.032] [Citation(s) in RCA: 41] [Impact Index Per Article: 41.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 05/01/2023] [Accepted: 05/08/2023] [Indexed: 06/03/2023]
Abstract
BACKGROUND & AIMS The cause of Crohn's disease (CD) is unknown, but the current hypothesis is that microbial or environmental factors induce gut inflammation in genetically susceptible individuals, leading to chronic intestinal inflammation. Case-control studies of patients with CD have cataloged alterations in the gut microbiome composition; however, these studies fail to distinguish whether the altered gut microbiome composition is associated with initiation of CD or is the result of inflammation or drug treatment. METHODS In this prospective cohort study, 3483 healthy first-degree relatives (FDRs) of patients with CD were recruited to identify the gut microbiome composition that precedes the onset of CD and to what extent this composition predicts the risk of developing CD. We applied a machine learning approach to the analysis of the gut microbiome composition (based on 16S ribosomal RNA sequencing) to define a microbial signature that associates with future development of CD. The performance of the model was assessed in an independent validation cohort. RESULTS In the validation cohort, the microbiome risk score (MRS) model yielded a hazard ratio of 2.24 (95% confidence interval, 1.03-4.84; P = .04), using the median of the MRS from the discovery cohort as the threshold. The MRS demonstrated a temporal validity by capturing individuals that developed CD up to 5 years before disease onset (area under the curve > 0.65). The 5 most important taxa contributing to the MRS included Ruminococcus torques, Blautia, Colidextribacter, an uncultured genus-level group from Oscillospiraceae, and Roseburia. CONCLUSION This study is the first to demonstrate that gut microbiome composition is associated with future onset of CD and suggests that gut microbiome is a contributor in the pathogenesis of CD.
Collapse
Affiliation(s)
- Juan Antonio Raygoza Garay
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Williams Turpin
- Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Sun-Ho Lee
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Michelle I Smith
- Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Ashleigh Goethel
- Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Anne M Griffiths
- Division of Gastroenterology, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Paul Moayyedi
- Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
| | - Osvaldo Espin-Garcia
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Biostatistics Department, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada
| | - Maria Abreu
- Division of Gastroenterology, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida
| | - Guy L Aumais
- Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
| | - Charles N Bernstein
- Inflammatory Bowel Disease Clinical and Research Center and Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Winnipeg, Canada
| | - Irit A Biron
- Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel
| | - Maria Cino
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Colette Deslandres
- Department of Hepatology and Pediatric Nutrition, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
| | - Iris Dotan
- Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel
| | - Wael El-Matary
- Pediatric Gastroenterology, Max Rady College of Medicine, University of Manitoba, Manitoba, Winnipeg, Canada
| | - Brian Feagan
- Departments of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
| | - David S Guttman
- Center for the Analysis of Genome Evolution and Function, University of Toronto, Toronto, Ontario, Canada
| | - Hien Huynh
- Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| | - Levinus A Dieleman
- Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Jeffrey S Hyams
- Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children's Medical Center, Hartford, Connecticut
| | - Kevan Jacobson
- Research Institute, British Columbia Children's Hospital, Vancouver, British Columbia, Canada
| | - David Mack
- Division of Gastroenterology, Hepatology & Nutrition, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, Canada
| | - John K Marshall
- Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
| | - Anthony Otley
- Division of Gastroenterology, Izaak Walton Killam Hospital, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Remo Panaccione
- Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Alberta, Canada
| | - Mark Ropeleski
- Gastrointestinal Diseases Research Unit, Department of Medicine, Queen's University, Kingston, Ontario, Canada
| | - Mark S Silverberg
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - A Hillary Steinhart
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Dan Turner
- The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Baruch Yerushalmi
- Pediatric Gastroenterology Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Andrew D Paterson
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Genetics and Genome Biology, The Hospital for Sick Children Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Wei Xu
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Biostatistics Department, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
| | - Kenneth Croitoru
- Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Zane Cohen Center for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.
| |
Collapse
|
3
|
Park BM, Jung BG, Lee JA, Lee BJ. Mitigating Effects of Tenebrio molitor Larvae Powder Administration in Mice with Dextran Sodium Sulfate (DSS)- Induced Colitis. Asian Pac J Cancer Prev 2023; 24:1751-1758. [PMID: 37247298 PMCID: PMC10495887 DOI: 10.31557/apjcp.2023.24.5.1751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 05/16/2023] [Indexed: 05/31/2023] Open
Abstract
BACKGROUND Ulcerative colitis (UC) is an inflammatory bowel disease that affects people worldwide. The causes of UC are diverse, and symptoms include diarrhea, weight loss, anemia, rectal bleeding, and bloody stools. Tenebrio molitor larvae have recently gained attention as edible insects with various physiological and medical effects. Research on the anti-inflammatory effects of ingesting Tenebrio molitor larvae powder (TMLP) is being actively conducted. In this study, TMLP was administered to mice with dextran sodium sulfate (DSS)-induced colitis to investigate its effects in reducing colitis symptoms. METHODS Mice were initially given 3% DSS in water to induce colitis and then feed containing 0%, 2%, or 4% TMLP. Pathologic changes in colon tissues were assessed by histology, and neutrophil levels were measured by myeloperoxidase (MPO) assay. Levels of IL-1β, IL-6, and TNF-α were measured using real-time PCR and ELISA assays, and IκB and NF-kB protein levels were measured by western blotting. RESULT Disease Activity Index (DAI) scores and MPO activity were reduced in TMLP-treated mice, and colon length increased as much as normal mice. Pathologic changes in the colon tissues of DSS-induced mice were attenuated, and the expression of inflammatory cytokine genes IL-1β, IL-6, and TNF-α decreased. Concomitant decreases in the protein expression of IL-1β and IL-6 were confirmed using ELISA. Western blotting revealed that levels of phosphorylated forms of IκB and NF-κB also decreased. CONCLUSION These results show that feeding TMLP to DSS-induced mice inhibited the typical inflammatory pathway of colitis. Therefore, TMLP shows potential as a food additive that can help treat colitis. .
Collapse
Affiliation(s)
- Bo Mi Park
- College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea.
| | - Bock Gie Jung
- College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea.
- Department of Pulmonary Immunology, University of Texas Health Science Center at Tyler, Tyler, TX 75708-3154, USA.
| | - Jin-A Lee
- Biology Department at Morrissey College of Arts and Sciences, Boston College, Chestnut Hill, MA 02467, USA.
| | - Bong Joo Lee
- College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea.
| |
Collapse
|
6
|
Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2022; 2022:6836942. [PMID: 35912148 PMCID: PMC9328974 DOI: 10.1155/2022/6836942] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 06/12/2022] [Accepted: 06/15/2022] [Indexed: 11/21/2022]
Abstract
Objective To examine the clinical efficacy and safety of Vitamin D in the treatment of ulcerative colitis in a systematic manner. Methods RCT studies on Vitamin D in the treatment of ulcerative colitis were searched from CNKI, Wanfang Data, PubMed, Cochrane Library, and Web of Science databases. RevMan 5.4 software was used for analysis. Results 10 articles were included, including 1077 patients. Meta-analysis results showed that when clinical efficacy was used as the outcome index, the clinical efficacy of the oral vitamin group was higher than that of the conventional treatment group (OR = 4.07, 95% CI 2.64-6.27), and the difference was statistically significant (Z = 6.38, P < 0.00001). When the Mayo risk score was used as the outcome index, the difference was statistically significant, indicating that oral Vitamin D significantly reduced the Mayo risk score (MD: -0.41, CI = (−0.47, −0.34), Z = 13.09, P < 0.00001). Using the intestinal mucosal barrier as the outcome index, the results showed that (1) the MDA group (MD = −0.75, 95% CI (-0.96~-0.53), P < 0.00001), (2) the DAO group (MD = −1.17, 95% CI (-1.39-0.95), P < 0.00001), and the Vitamin D group could effectively improve intestinal mucosal barrier function after sensitivity analysis (MD = −1.00, 95% CI (-1.08-0.92), P < 0.00001). When inflammatory factors were used as outcome indicators, IL-6, TNF-α, and CRP groups had statistical significance (MD = −4.50, 95% CI (-5.13-3.87), P < 0.00001); MD = −7.27, 95% CI (18.96-5.58), P < 0.00001; and MD = −1.49, 95% CI (-1.76~-1.23), P < 0.00001, respectively). When the incidence of adverse reactions was used as the outcome indicator (OR = 0.73, 95% CI (0.34-1.32), P = 0.23), there was no significant difference between the two groups. Conclusion Vitamin D combined with mesalazine is effective in the treatment of ulcerative colitis, by improving the Mayo score and intestinal barrier function, and reducing inflammatory factors, with no significant safety difference. However, due to the quality of the included researches, more RCT researches needed to provide sufficient evidence to support clinical application. This study is registered with INPLASY 202250044.
Collapse
|
8
|
Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, Coufal S, Thon T, Mihula M, Modrak M, Kverka M, Bajer L, Kostovcikova K, Drastich P, Hercogova J, Novakova M, Vasatko M, Lukas M, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy. Cells 2021; 10:3188. [PMID: 34831411 PMCID: PMC8617723 DOI: 10.3390/cells10113188] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Revised: 11/11/2021] [Accepted: 11/12/2021] [Indexed: 12/17/2022] Open
Abstract
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).
Collapse
Affiliation(s)
- Dagmar Schierova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Radka Roubalova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Martin Kolar
- IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic; (M.K.); (M.V.); (M.L.)
| | - Zuzana Stehlikova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Filip Rob
- Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic; (F.R.); (J.H.); (M.N.)
| | - Zuzana Jackova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Stepan Coufal
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Tomas Thon
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Martin Mihula
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Martin Modrak
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Miloslav Kverka
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Lukas Bajer
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
- Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic;
| | - Klara Kostovcikova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Pavel Drastich
- Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic;
| | - Jana Hercogova
- Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic; (F.R.); (J.H.); (M.N.)
| | - Michaela Novakova
- Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic; (F.R.); (J.H.); (M.N.)
| | - Martin Vasatko
- IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic; (M.K.); (M.V.); (M.L.)
| | - Milan Lukas
- IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic; (M.K.); (M.V.); (M.L.)
- Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic
| | - Helena Tlaskalova-Hogenova
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| | - Zuzana Jiraskova Zakostelska
- Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic; (D.S.); (R.R.); (Z.S.); (Z.J.); (S.C.); (T.T.); (M.M.); (M.M.); (M.K.); (L.B.); (K.K.); (H.T.-H.)
| |
Collapse
|